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ABSTRACT. Bacterial DNA gyrase and topoisomerase IV control the topological state of DNA 
during replication and are validated targets for antibacterial drug discovery. Starting from our 
recently reported 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-based DNA gyrase B inhibitors, we 
replaced  their central core with   benzothiazole-2,6-diamine scaffold and interchanged 
substituents in positions 2 and 6. This resulted in equipotent nanomolar inhibitors of DNA gyrase 
from Escherichia coli displaying improved inhibition of Staphylococcus aureus DNA gyrase  
and topoisomerase IV from both bacteria. Compound 27 was the most balanced inhibitor of 
DNA gyrase and topoisomerase IV both from E. coli and S. aureus. The crystal structure of the 
2-((2-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzothiazol-6-yl)amino)-2-oxoacetic acid (24) 
in complex with E. coli DNA gyrase B revealed the binding mode of the inhibitor in the ATP-
binding pocket. Only some compounds possessed weak antibacterial activity against Gram-
positive bacteria. These results provide a basis for structure-based optimization towards dual 
DNA gyrase and topoisomerase IV inhibitors with antibacterial activity. 
 
 
 
 
 
INTRODUCTION 
In the middle of the 20th century, antibiotics were considered to be a powerful discovery that 
made infectious diseases a problem of the past. Today, it is clear that some of the antibacterial 
compounds discovered during the last century were only a short-term solution for the treatment 
of infectious diseases because bacterial resistance to these drugs is increasing and treatments are 
becoming less effective.1,2 Although the discovery of antibiotics is a very important achievement 
for mankind, the greatest challenges in antibacterial research are yet to come. There is a need for 
new antibacterial compounds that have new mechanisms of action with activity against resistant 
bacterial strains, and the search for new antibacterial agents remains a significant challenge for 
the future.    
Bacterial DNA gyrase is a topoisomerase type II enzyme that has attracted attention since its 
discovery in 1976, when it was first isolated from Escherichia coli3 and identified as a target of 
the already known aminocoumarin class of antibacterial compounds. In the 1990s, when the 
crystal structure of the N-terminal fragment of DNA gyrase had already been solved,4 
topoisomerase IV, a bacterial enzyme with a similar structure, function, and inhibitor 
susceptibility to DNA gyrase was identified.5,6   
DNA gyrase and topoisomerase IV catalyze changes in DNA topology by breaking and 
rejoining double stranded DNA. In particular, DNA gyrase introduces negative supercoils in 
DNA in front of the replication fork, while topoisomerase IV is important for decatenation 
during DNA replication. Thus, both enzymes are involved in very important processes during 
DNA replication and are essential for cell viability. Both enzymes are ATP-fueled 
heterotetrameric proteins; DNA gyrase is composed of two A subunits (GyrA) and two B 
subunits (GyrB), whereas topoisomerase IV consists of two C subunits (ParC) and two E 
 
 
 
 
 
subunits (ParE), which are homologous to GyrA and GyrB, respectively.7 The GyrA and ParC 
subunits are involved in DNA transit, while the GyrB and ParE subunits contain an ATP-binding 
domain.8 Type II topoisomerase is also found in eukaryotic cells, but unlike the prokaryotic 
enzymes, eukaryotic topoisomerase II is homodimeric. This difference in structure makes 
selective targeting of prokaryotic topoisomerase II possible.7 The similarities in the structure of 
DNA gyrase and topoisomerase IV offer an exceptional opportunity for the dual targeting of 
these enzymes by new antibacterial compounds, thereby reducing the probability of bacteria to 
develop target-based resistance against them.9 Thus, the selectivity of targeting prokaryotic 
topoisomerase II, the potential of dual targeting, and the well-known structure of these enzymes 
makes both DNA gyrase and topoisomerase IV attractive targets in the challenging search for 
new antibacterial compounds. 9-17         
DNA gyrase and topoisomerase IV have been recognized as targets of aminocoumarin and 
quinolone classes of antibacterial compounds. However, these two classes of inhibitors target 
different parts of the enzymes. Well known and widely used quinolones target GyrA and ParC 
subunits, while aminocoumarin class inhibitors target GyrB and ParE subunits. Novobiocin 
(Figure 1), a natural product aminocoumarin class inhibitor of DNA gyrase and topoisomerase 
IV discovered in the mid-1950s, targets ATP-binding sites at the GyrB and ParE subunits. It is 
the only GyrB inhibitor to be used in clinical practice, but despite its good pharmacokinetic 
profile, it was withdrawn from the market primarily due to its toxicity and also due to the high 
rate of resistance development. Coumermycin A1 and clorobiocin (Figure 1) are two other 
aminocoumarin natural products that showed good inhibitory activities against DNA gyrase B, 
but they never reached the market because of their undesirable toxicity profiles. Numerous 
studies toward the development of improved novobiocin analogues were unsuccessful, mainly 
 
 
 
 
 
because of their undesirable pharmacokinetic profile and lack of inhibitory or microbiological 
activity. Thus, novobiocin is still the only GyrB inhibitor that was used clinically and also the 
only GyrB inhibitor that has progressed beyond Phase I clinical trials.18 
 
 
 
Figure 1. Structures of the DNA gyrase B inhibitors novobiocin and clorobiocin.  
 
  
Figure 2. Examples of dual inhibitors of GyrB and ParE possessing (a) benzimidazole (b) 
bithiazole, (c) thiazolopyridine, (d) pyrrolopyrimidine, (e) imidazopyridine, and (f) 
benzothiazole scaffolds.  
 
Determination of the crystal structure of DNA gyrase B in complex with adenylyl 5’-(β,γ-
imido)-triphosphate (ADPNP) in 1991 and later with other known inhibitors of DNA gyrase 
B18,19,20 provided significant information about the most important inhibitor interactions in the 
protein ATP-binding site. This information created a solid basis for the structure-based design of 
 
 
 
 
 
inhibitors over the years and led to discovery of several new scaffolds that had good potential for 
inhibition of DNA gyrase and topoisomerase IV. Over the years, using scaffold hopping 
approaches21 and exploiting opportunities offered to medicinal chemistry by aromatic 
heterocycles,22 benzimidazole ureas,23 bithiazoles,24 thiazolopyridines,25 pyrrolopyrimidines,26 
imidazopyridines,27 benzothiazoles 28,29 (Figure 2) and other structural types18 have been studied 
as dual inhibitors of GyrB and ParE subunits of bacterial gyrase and topoisomerase IV.9,14  
 
RESULTS AND DISCUSSION 
Design. Our research group has recently reported the discovery of novel structural classes of 
DNA gyrase inhibitors based on 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole30 and N-phenyl-4,5-
dibromopyrrolamide31 scaffolds inspired by the marine natural product oroidin (Figure 3). We 
obtained the crystal structure of 02 in complex with E. coli GyrB and demonstrated that the 4,5-
dibromo-1H-pyrrole-2-carboxamide moiety of 01 and 02 bound to the ATP binding site of GyrB 
participates in a hydrogen bond with the Asp73 carboxylate group and a conserved water 
molecule, whereas the terminal carboxylic acid moiety is involved in interactions with Arg76 
and/or Arg136.30,31 Based on the crystal structure of the E. coli GyrB - 02 complex and potent 
inhibition of E. coli DNA gyrase by 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole class inhibitors in 
conjunction with their weaker inhibition of Staphylococcus aureus DNA gyrase and E. coli and 
S. aureus topoisomerase IV, we examined the effects of different structural modifications of the 
parent compound 01 on the inhibition of both enzymes. First, the 4,5,6,7-tetrahydrobenzo[1,2-
d]thiazole moiety was replaced by a planar aromatic benzothiazole scaffold to enable additional 
cation - π interaction of the benzene ring with Arg76 within the Glu50-Arg76 salt bridge, which 
is not present in the 4,5,6,7-tetrahydrobenzo[1,2-d] series and was shown to be important for the 
 
 
 
 
 
strong inhibition of DNA gyrase B.18 The benzothiazole scaffold additionally made possible the 
substitution pattern which proved to be successful in the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole 
series.30  Second, because our docking experiments (Figure 4) suggested similar binding modes 
of compounds incorporating the pyrrole-2-carboxamido moiety at positions 6 (Series A) and 2 
(Series B) of the central heterocyclic core, series B analogues of the parent compound 01 were 
prepared in addition to series A compounds. Third, the dibromopyrrole moiety was replaced by a 
smaller dichloropyrrole moiety to possibly improve multiple inhibition against S. aureus DNA 
gyrase and E. coli and S. aureus topoisomerase IV because these three enzymes possess a 
smaller hydrophobic pocket compared to that of E. coli DNA gyrase.30 Finally, the effect of the 
length of the ester or carboxylic acid moieties on the multiple inhibition of DNA gyrase and 
topoisomerase IV was evaluated.  As demonstrated below, this resulted in an improved inhibitor 
series that possesses inhibitory activity against topoisomerase IV from both bacterial strains. The 
crystal structure of series B compound 24 in complex with E. coli DNA gyrase B revealed the 
binding mode of the studied benzothiazole class of compounds, thus providing a solid basis for 
structure-based design and optimization of this promising class of ATP-binding site targeting 
DNA gyrase B inhibitors.  
  
Figure 3. Design of series A and B benzothiazole-2,6-diamine-based DNA gyrase B inhibitors.  
 
 
 
 
 
a b  
Figure 4. The binding mode of a) inhibitor 24 (in green sticks) and b) inhibitor 13 (in orange 
sticks) in the ATP-binding site of E. coli DNA gyrase B (PDB code: 4DUH) as predicted by 
docking with LeadIT. The ligand and neighboring protein side chains are shown as stick models, 
colored according to the chemical atom type (Cligand 24 in green, Cligand 13 in orange, CGyrB in gray, 
N in blue, O in red, S in yellow, and Br in brown). Hydrogen bonds with their lengths in Å are 
indicated as black dotted lines. Figure was prepared by PyMOL. 
 
Chemistry. The synthesis of the series A compounds with the pyrrole-2-carboxamido group 
attached at position 6 of the benzothiazole-2,6-diamine scaffold is presented in Scheme 1.  
Acylation of 1 with appropriate acyl chloride (ethyl oxalyl chloride, methyl malonyl chloride or 
methyl succinyl chloride) in the presence of triethylamine in 1,4-dioxane at room temperature 
afforded compounds 2, 3 and 4. The reduction of the nitro group of 2-4 using catalytic 
hydrogenation in the presence of 10% Pd/C in methanol or ethanol yielded amines 5, 6 and 7. 
These were acylated with freshly prepared 4,5-dibromo-1H-pyrrole-2-carbonyl chloride or 4,5-
dichloro-1H-pyrrole-2-carbonyl chloride in the presence of pyridine in dichloromethane to obtain 
esters 8-12. Compounds 8 and 10 were hydrolyzed with 1 M sodium hydroxide in methanol to 
produce carboxylic acids 13 and 14. All attempts to hydrolyze malonic acid derivatives 9 and 12 
 
 
 
 
 
were unsuccessful due to decarboxylation that, surprisingly, did not compromise the hydrolysis 
of the  series B esters 18-23 (Scheme 2) and related 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole 
analogs.30   
Scheme 1. Synthesis of Series A compoundsa 
 
aReagents and conditions: (a) ethyl oxalyl chloride (for 2), methyl malonyl chloride (for 3) or 
methyl succinyl chloride (for 4), Et3N, 1,4-dioxane, rt, 4 h; (b) H2, 10% Pd/C, EtOH (for 5) or 
MeOH (for 6, 7), rt, 24 h; (c) i) 4,5-dibromo-1H-pyrrole-2-carboxylic acid (for 8, 9 and 10) or 
4,5-dichloro-1H-pyrrole-2-carboxylic acid (for 11 and 12), oxalyl chloride, DCM, rt, 15 h, then 
ii) 5 (for 8 and 11), 6 (for 9 and 12) or 7 (for 10), pyridine, DCM, rt, 2 h; (d) 1 M NaOH, MeOH, 
rt, 24 h.  
Synthesis of compounds from series B started from the commercially available 6-nitro-
benzothiazol-2-amine (1), which was catalytically hydrogenated to benzothiazole-2,6-diamine 
(15) in a Parr hydrogenator at 2.1 bar pressure, using ethanol as a solvent and 10% Pd/C as a 
catalyst. The diamine 15 was further coupled with 2,2,2-trichloro-1-(4,5-dibromo-1H-pyrrol-2-
yl)ethan-1-one or 2,2,2-trichloro-1-(4,5-dichloro-1H-pyrrol-2-yl)ethan-1-one in the presence of 
 
 
 
 
 
Na2CO3 as a base in N,N-dimethylformamide at 80 °C to obtain pyrrolamides 16 and 17. 
Acylation of 16 and 17 with ethyl oxalyl chloride, methyl malonyl chloride or methyl succinyl 
chloride at room temperature in the presence of triethylamine in 1,4-dioxane afforded esters 18-
23, which were hydrolyzed to carboxylic acids 24-29 upon treatment  with 1 M sodium 
hydroxide in methanol  (Scheme 2). 
Scheme 2. Synthesis of Series B Compoundsa 
 
aReagents and conditions: (a) H2 (2.1 bar), 10% Pd/C, EtOH, rt, 6 h; (b) 2,2,2-trichloro-1-(4,5-
dibromo-1H-pyrrol-2-yl)ethan-1-one (for 16) or 2,2,2-trichloro-1-(4,5-dichloro-1H-pyrrol-2-
yl)ethan-1-one (for 17), DMF, Na2CO3, 80 °C, 5 h; (c) ethyl oxalyl chloride (for 18 and 21), 
methyl malonyl chloride (for 19 and 22), methyl succinyl chloride (for 20 and 23), Et3N, 1,4-
dioxane, rt, 12 h; (d) 1 M NaOH, MeOH, rt, 24 h. 
 
In vitro inhibition of DNA gyrase and topoisomerase IV. Synthesized benzothiazole 
derivatives were evaluated for their inhibitory activity against DNA gyrase and topoisomerase IV 
from both E. coli and S. aureus in supercoiling and decatenation assays, respectively. The 
inhibitory activities of the tested compounds are presented in Tables 1 and 2 as IC50 values. 
 
 
 
 
 
Inhibitory activities against DNA gyrase  
In the series A compounds, in which the 4,5-dichloro- or 4,5-dibromopyrrolamido moiety is 
attached at the position 6 of the benzothiazole ring, the most favorable acyl substituent at 
position 2 proved to be the oxalyl group, both in the ester and the free carboxylic acid form as 
demonstrated by the most potent inhibitor 13 (IC50 = 38 nM) of  E. coli DNA gyrase among 
compounds in the Series A (Table 1). The dichloro ester analogues 11 and 12 displayed weaker 
inhibition of E. coli DNA gyrase than the corresponding dibromo analogues, so the respective 
carboxylic acids were not prepared. The inhibitory potency of dibromo ethyl oxalate 8 equaled 
that of the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole analogue (IC50 = 100 nM) while the 
methylmalonate and methylsuccinate esters 9 and 10 were found to be twofold and ninefold 
weaker inhibitors of E. coli DNA gyrase than the corresponding 4,5,6,7-tetrahydrobenzo[1,2-
d]thiazole analogues. 30 The carboxylic acid inhibitors 13 (IC50 = 38 nM) and 14 (IC50 = 57 nM) 
were equipotent with the corresponding 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole analogues (oxalyl 
analogue: IC50 = 58 nM; succinyl analogue: IC50 = 49 nM).
30 Compounds from the Series A did 
not display a substantial S. aureus DNA gyrase inhibition. (Table 1).   
From the inhibitory activities of series B compounds 16 and 17, shown in Table 2 it can be 
concluded that the 4,5-dibromo-1H-pyrrolamide moiety attached at position 2 on the 
benzothiazole ring contributes to the affinity for the ATP-binding site of E. coli DNA GyrB more 
than the 4,5-dichloro-1H-pyrrolamide moiety attached at the same position. This trend was also 
observed for the activities of other compounds from Series B containing the 4,5-dibromo-1H-
pyrrolamide moiety (c.f. 18 vs. 21 and 20 vs. 23, 24 vs. 27 and 26 vs. 29), with the exception of 
the malonyl pairs 19 and 22 and 25 and 28, in which a trend of stronger inhibition by the 4,5-  
 
 
 
 
 
Table 1. Inhibition of E. coli and S. aureus DNA gyrase and topoisomerase IV by the 
benzothiazole compounds containing the pyrrole-2-carboxamido moiety at position 6 on the 
benzothiazole core (Series A). 
 
    
 
 
 
 
 
      
 
 
dichloro-1H-pyrrolamide compounds was observed. On the contrary, the differences between the 
dibromopyrrole and dichloropyrrole compounds were not straightforward for inhibition of DNA 
gyrase from S. aureus. Ethyl oxalyl, methyl malonyl and methyl succinyl moieties attached at 
position 6  of the benzothiazole ring improved the inhibitory activities of the dichloropyrrole 
compounds 21-23 but not of the dibromopyrrole compounds 18-20  against E. coli DNA gyrase, 
with the methyl malonyl derivative 22 (IC50 = 0.22 μM) being the most potent inhibitor in this 
ester series. In the carboxylic acid series (compounds 24-29) the measured IC50 values for 
 
compound X n 
 
R 
DNA gyrase  
IC50 [μM] 
topoisomerase IV  
 IC50 [μM]  
E. coli S. aureus E. coli S. aureus 
novobiocin - - - 0.17 0.040 11 27 
8 Br 0 Et 0.081 ± 0.05 > 100 > 100 > 100 
9 Br 1 Me 0.24 ± 0.02 > 100 > 100 > 100 
10 Br 2 Me 0.87 ± 0.21 > 100 > 100 > 100 
11 Cl 0 Et 1.8 ± 0.4 > 100 > 100 > 100 
12 Cl 1 Me 7.9 ± 2.1 > 100 > 100 > 100 
13 Br 0 H 0.038 ±  0.001 > 100 5.4 ± 1.0 2.5 ± 0.2 
14 Br 2 H 0.057 ± 0.018 > 100 4.5 ± 0.7 2.2 ± 0.3 
 
 
 
 
 
inhibition of DNA gyrase from E. coli were all in the nanomolar range, due to the contribution of 
the carboxylate group interaction with Arg136. The most potent inhibitors in the dibromopyrrole 
carboxylic acid series were succinyl and oxalyl derivatives 26 (IC50 = 33 nM) and 24 (IC50 = 58 
nM), while for the dichloropyrrole compounds the most potent inhibitor was oxalyl compound 
27 with an IC50 value of 87 nM. The affinity of compound 24 for DNA gyrase B from E. coli was 
further confirmed by surface plasmon resonance (SPR) (for experimental details see Ref. 29) 
with a Kd of 0.23 μM. The inhibition of S. aureus DNA gyrase was observed only for the 
dibromopyrrole carboxylic acid 25 (IC50 = 5.6 µM) and dichloropyrrole carboxylic acids 27-29, 
with IC50 values in the range of 0.51 to 94 µM. Generally, all of the compounds from Series B 
displayed weaker inhibition of S. aureus DNA gyrase  compared to  E. coli gyrase. It is worth  
noting the  low micromolar activity of malonyl compounds 25 in the dibromo series (IC50 = 5.6 
μM) and 28 in the dichloro series (IC50 = 8.5 μM) against S. aureus gyrase. The nanomolar 
activity of the dichloro oxalyl derivative 27 (IC50 = 0.51 μM) in comparison to dibromo analogue 
24 (IC50 >100 μM), as well as to malonyl analogue 28 (IC50 = 8.5 μM) and succinyl analogue 29 
(IC50 = 94 μM) is also noteworthy, indicating that the carboxylic acid moiety and small changes 
in the length of the acyl moiety (c.f. 24 vs.25, 27 vs. 28) are important for the binding of Series B 
compounds to the ATP-binding site of S. aureus DNA gyrase. In addition, substitution in the 
pyrrole ring (c.f. 24 vs. 27) is important for the orientation of the whole molecule in the binding 
pocket of S. aureus DNA gyrase. The main difference between the compounds from the Series B 
(pyrrole-2-carboxamido group at position 2) and Series A (pyrrole-2-carboxamido group at 
position 6) is that the compounds in series B exhibited better inhibitory activity against S. aureus 
DNA gyrase, while their inhibitory activity against E. coli DNA gyrase remained in the 
nanomolar range. 
 
 
 
 
 
Table 2. Inhibition of E. coli and S. aureus DNA gyrase and topoisomerase IV by the 
benzothiazole compounds containing the pyrrole-2-carboxamido moiety at position 2 on the 
benzothiazole core (Series B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitory activities against topoisomerase IV 
 
compound X n R 
DNA gyrase 
IC50 [μM] 
topoisomerase IV 
IC50 [μM] 
E. coli S. aureus E. coli S. aureus 
novobiocin - - - 0.17 0.040 11 27 
16 Br - - 2.0 ± 0.2 > 100 > 100 > 100 
17 Cl - - > 100 > 100 > 100 > 100 
18 Br 0 Et 29 ± 6 > 100 > 100 > 100 
19 Br 1 Me 2.0 ± 0.4 > 100 > 100 > 100 
20 Br 2 Me 7.0 ± 0.9 > 100 > 100 > 100 
21 Cl 0 Et > 100 > 100 > 100 > 100 
22 Cl 1 Me 0.22 ± 0.02 > 100 > 100 > 100 
23 Cl 2 Me 35 ± 12 > 100 > 100 > 100 
24 Br 0 H 
0.058 ± 0.031 
> 100 13 ± 3 10 ± 2 
25 Br 1 H 0.14 ± 0.06 5.6 ± 2.6 45 ± 5 17 ± 3 
26 Br 2 H 0.033 ± 0.025 > 100 7.2 ± 1.3 26 ± 1 
27 Cl 0 H 0.087 ± 0.001 0.51 ± 0.23 1.8 ± 0.8 1.7 ± 0.8 
28 Cl 1 H 0.12 ± 0.02 8.5 ± 1 5.19 ± 4.7 2.4 ± 1.3 
29 Cl 2 H 0.43 ± 0.11 94 ± 25 5.3 ± 0.4 28 ± 4 
 
 
 
 
 
Generally, the inhibitory potencies of most of the Series B compounds against topoisomerase 
IV were lower than those against DNA gyrase for the E. coli enzymes but for the S. aureus 
enzymes, the IC50 values for the inhibition of both enzymes were more comparable (Tables 1 and 
2). Inhibition of topoisomerase IV by most of the active compounds (13, 14, and 24-29) was 
better than or comparable to that of novobiocin (IC50 (E. coli) = 11 µM; IC50 (S. aureus) = 27 
µM). The esters 8-12 and 18-23 did not show any promising activity, which indicates that a 
carboxylic acid moiety is required for the binding of the compounds in the ATP-binding site of 
topoisomerase IV. All of the final carboxylic acids (13, 14, and 24-29) from both series A and B 
exhibited low micromolar activities against topoisomerase IV from both E. coli and S. aureus. 
Compounds 25, 27 and 28 were found to be especially interesting for further studies because 
they showed promising inhibitory activities against all four tested enzymes. In particular, 4,5-
dichloropyrrole-based benzothiazole inhibitor 27 exhibited well-balanced multiple inhibition of 
all four enzymes in the nanomolar and low micromolar range (0.087 – 1.8 µM). 
Antibacterial activity. All of the compounds from series A and series B were tested against two 
Gram-positive (Staphylococcus aureus ATCC 25923, Enterococcus faecalis ATCC 29212) and 
two Gram-negative (Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853) 
bacterial strains. In general, the compounds did not show significant antibacterial activities 
against either Gram-positive or Gram-negative bacteria. The only notable activities were 
observed against Gram-positive E. faecalis for compounds 25 and 11 which showed 59% and 
47% inhibition of the growth of E. faecalis at a 50 µM concentration after 24 h incubation, 
respectively. None of the final compounds showed significant antibacterial activity against the 
tested Gram-negative bacteria. Because a possible reason for the absence of the antibacterial 
activity of compounds against Gram-negative bacteria could be their affinity for efflux pumps, 
 
 
 
 
 
we tested the compounds 17-19, 21-25, 27 and 29 in ΔtolC E. coli, an efflux deficient strain 
derived from wild-type E. coli ECM1194 that lacks a functional tolC gene that encodes the 
essential outer membrane component of the multicomponent efflux pump (for experimental 
details see Ref. 30). We found that compound 25 exhibited more potent antibacterial activity 
(MIC < 16 µg/mL) in ΔtolC, than in the wild type E. coli strain that contained efflux pump (MIC 
> 256 µg/mL). These results may explain the weak antibacterial activity of 25 and similar 
compounds against both Gram-negative bacterial strains tested, with only 12%  inhibition of the 
growth of E. coli and 11% inhibition of the growth of P. aeruginosa after 24 h incubation.    
       
X-Ray crystallography and molecular modeling. A detailed binding mode of the series B 
inhibitor 24 in the ATP-binding site of the 43 kDa N-terminal fragment of the E. coli DNA 
gyrase B (residues Gly15 to Thr392) was revealed from the X-ray co-crystal structure, which 
was solved to a resolution of 2.83 Å (PDB code: 5L3J). The electron density for most of the 
ligand is well defined, but is missing for the terminal carboxylate group (Figure 5), which can 
probably be attributed to its flexibility in the binding site. Similar situation was observed in the 
co-crystal structure of E. coli DNA gyrase in complex with N-phenyl-4,5-dibromopyrrolamide 
inhibitor, where the mobility of the inhibitor in the binding site was also shown through 
molecular dynamics simulation.31 In contrast, the high resolution crystal structure of bithiazole 
inhibitor in complex with E. coli DNA gyrase (PDB entry: 4DUH) revealed a hydrogen bond 
between the inhibitor and Gly101 carbonyl oxygen, which stabilized the Gly97-Ser108 flexible 
loop, decreased ligand flexibility and enhanced chances for obtaining a high resolution 
structure.24 Lack of the structural feature in this series of the benzothiazole inhibitors, enabling 
hydrogen bonding with amino residues of the Gly97-Ser108 flexible loop, thus probably also 
 
 
 
 
 
contributed to the higher mobility of ligand in the binding site and consequently to the lower 
crystal structure resolution of E. coli DNA gyrase – 24 complex. 
The orientation and conformation of the terminal carboxylate group of 24 was hence modeled 
in two different ways (Figure 5; model 1, model 2) and is located in the vicinity of Arg76 and 
Arg136, which are usually in contact with DNA gyrase B inhibitors.9,18 However, the electron 
density for the Arg76 side chain is missing in the experimental data and no hydrogen bonds can 
be predicted. The 4,5-dibromopyrrolamide moiety of 24 is bound to the adenine binding pocket, 
where a hydrogen bond between the pyrrole NH group and Asp73 side chain is formed. 
However, due to the X-ray structure resolution of 2.83 Å, only a few water molecules were 
modeled based on the electron density and the conserved water molecule was not observed in the 
structure. Therefore, a hydrogen bond between the inhibitor carbonyl group and Asp73 side 
chain bridged by this water molecule could not be observed. The 4,5-dibromopyrrole moiety 
forms additional hydrophobic contacts with Val43, Asn46, Val71, Val120, Thr165 and Val167, 
while the benzothiazole scaffold forms hydrophobic interactions with Glu50, Gly77, Ile78 and 
Pro79. 
Possible binding modes of DNA gyrase inhibitors of the benzothiazole-2,6-diamine series A 
and B were also studied following our recently described docking protocol,30 using LeadIT and 
the high resolution structure of E. coli DNA gyrase in complex with a bithiazole inhibitor.24 
Comparison of the predicted (Figure 4a) and experimental binding mode (Figure 5a) of 24 in the  
 
 
 
 
 
 
a b  
Figure 5. X-ray crystal structure of E. coli DNA gyrase B in complex with ligand 24 (PDB code: 
5L3J): a) model 1; b) model 2. The ligand and neighboring protein side chains are shown as stick 
models, that are colored according to the chemical atom type (Cligand in green for model 1 and in 
yellow for model 2, CGyrB in gray, N in blue, O in red, S in yellow, and Br in brown). The ligand 
molecule is shown superimposed with the refined 2Fo−Fc electron density map contoured at 1.0 
σ. Hydrogen bonds are indicated as black dotted lines. Figure was prepared by PyMOL. 
 
E. coli DNA gyrase ATP-binding site shows similar conformation of the ligand, while its 
position is slightly different. The docking predicts the formation of hydrogen bonds between the 
terminal oxalate moiety and Arg76 and Arg136 side chains that could not be observed in the X-
ray structure (Figure 5). Such hydrogen bonds are predicted for all oxalic (8, 11, 13, 18, 21, 24 
and 27), malonic (9, 12, 19, 22, 25, and 28) and succinic acid (10, 14, 20, 23, 26 and 29) 
derivatives in both series A and series B. As an example, the predicted binding mode of series A 
compound 13, which has the opposite substitution as 24, is presented in Figure 4b. 
 
CONCLUSION 
In summary, replacement of the central core of 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-based 
DNA gyrase B inhibitors29 with a planar benzothiazole-2,6-diamine scaffold and moving the 4,5-
 
 
 
 
 
dihalopyrrole-2-carbonyl group from N-6 to N-2 of the central core resulted in two series of 
nanomolar inhibitors. These compounds were nearly equipotent with the 4,5,6,7-
tetrahydrobenzo[1,2-d]thiazole compounds as  inhibitors of E. coli DNA gyrase but displayed 
improved inhibition of S. aureus DNA gyrase and topoisomerase IV from both bacteria. A 
crystal structure of 2-((2-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzothiazol-6-yl)amino)-2-
oxoacetic acid (24) in complex with E. coli DNA gyrase B solved to a resolution of 2.83 Å 
revealed the binding mode of the inhibitor in the ATP-binding pocket of the enzyme. In general, 
no significant antibacterial activity against both Gram-negative and Gram-positive bacteria was 
observed, most likely due to efflux of inhibitors. Some of the compounds possessed only weak 
antibacterial activity against Gram-positive E. faecalis. The results of this study provide a good 
starting point for structure-based design of improved ATP-competitive DNA gyrase and 
topoisomerase IV inhibitors with antibacterial activity. In this respect, compounds 25, 27 and 28 
are especially interesting for further studies because they showed promising well balanced 
multiple inhibiton  in the nanomolar/low micromolar range against DNA gyrase and 
topoisomerase IV both in E. coli and S. aureus.   
 
EXPERIMENTAL SECTION 
 
Chemistry. The chemicals obtained from Sigma-Aldrich (St. Louis, MO, USA), Acros 
Organics (Geel, Belgium), and Appollo Scientific (Stockport, UK) were used without further 
purification unless otherwise stated. Analytical TLC was performed on 0.25 mm silica gel Merck 
60 F254 plates, using visualization with UV light and spray reagents. Column chromatography 
was carried out on Merck silica gel 60 (particle size 240-400 mesh). Melting points were 
 
 
 
 
 
determined on a Reichert hot stage microscope and are uncorrected. 1H NMR and 13C spectra 
were recorded at 400 and 100 MHz, respectively, on a Bruker AVANCE III spectrometer in 
DMSO-d6 or CDCl3 solution with TMS as an internal standard at room temperature. IR spectra 
were obtained using a Thermo Nicolet Nexus 470 ESP FT-IR spectrometer. Mass spectra were 
recorded on a VG Analytical Autospec Q mass spectrometer. HPLC analyses were run on an 
Agilent Technologies 1100 instrument (Agilent Technologies, Santa Clara, CA, USA) with a 
G1365B UV-VIS detector, a G1316A thermostat, and a G1313A autosampler using a 
Phenomenex Luna 5-μm C18 column (4.6 mm × 150 mm or 4.6 mm × 250 mm, Phenomenex, 
Torrance, CA, USA) and a flow rate of 1.0 mL/min. The eluent consisted of 0.1 % trifluoroacetic 
acid in water (A) and methanol (B); gradient, 90 % A to 10 % A in 20 min, then 5 min 10 % A; 
flow rate 1.0 mL/min; injection volume, 10 μL. All tested compounds had a purity of at least 
95% by HPLC and passed the PAINS filter (see below).   
General procedure A. Synthesis of compound 2, 3 and 4.  
6-Nitro-benzothiazol-2-amine (1) (1.95 g, 10.0 mmol) was dissolved in 1,4-dioxane (100 mL), 
triethylamine (2.09 mL, 15.0 mmol) was added and the mixture was cooled down to 0 °C. Ethyl 
oxalyl chloride (1.68 mL, 15.0 mmol), methyl malonyl chloride (1.61 mL, 15.0 mmol) or methyl 
succinyl chloride (1.85 mL, 15.0 mmol) were added dropwise to the mixture and the reaction 
mixture was stirred for additional 3 h at room temperature, whereupon saturated NaHCO3 
solution was added to quench the reaction. The reaction mixture was concentrated in vacuo, 
dissolved in ethyl acetate and the solution was washed with 3 × 10 mL saturated NaHCO3, 3 × 
10 mL 10% citric acid, 3 × 10 mL water and 3 × 10 mL brine. If the product precipitated 
between the ethyl acetate and water phase it was collected by filtration. The ethyl acetate phase 
 
 
 
 
 
was dried over sodium sulfate and concentrated. The combined crude products were 
recrystallized from ethyl acetate.   
Ethyl 2-((6-nitrobenzo[d]thiazol-2-yl)amino)-2-oxoacetate (2). Prepared according to general 
procedure A from compound 1 (2.00 g, 10.2 mmol); yellow crystals, yield 2.56 g (85 %); mp 
225-228 °C; IR (ATR) ν 3267, 3096, 1699, 1573, 1541, 1513, 1471,1441, 1412, 1377, 1346, 
1333, 1289, 1270, 1154, 1124, 1041, 1011, 959, 903, 857, 841, 828, 742, 719 cm-1; 1H NMR 
(400 MHz, DMSO-d6) δ 1.34 (t, 3H, J = 7.1 Hz, CH3CH2 ), 4.34 (q, 2H, J = 7.1 Hz, CH3CH2), 
7.97 (d, 1H, 3J = 8.9 Hz, Ar-H4), 8.31 (dd, 1H, 3J = 8.9 Hz, 
4J = 2.4 Hz,  Ar-H5), 9.12 (dd, 1H, 
4J = 2.4 Hz), 13.64 (s br, 1H, CONH) ppm; 13C NMR (100 MHz, DMSO-d6) δ 13.71, 62.85, 
119.19, 120.96, 121.83, 132.27, 143.30, 152.86, 157.43, 158.48, 163.03 ppm; HRMS (ESI+) m/z 
for C11H8N3O5S ([M-H]
-): calcd. 294.0185, found 294.0189.    
Methyl 3-((6-nitrobenzo[d]thiazol-2-yl)amino)-3-oxopropanoate (3). Prepared according to 
general procedure A from compound 1 (1.55 g, 7.94 mmol); yellow crystals, yield 1.60 g (68 %); 
mp 199-202 °C; IR (ATR) ν 2978, 1733, 1665, 1609, 1575, 1548, 1509, 1475, 1446, 1434, 1412, 
1330, 1280, 1235, 1202, 1168, 1152, 1125, 1045, 1018, 977, 900, 834, 807, 746, 720 cm-1; 1H 
NMR (400 MHz, DMSO-d6) δ 3.68 (s, 3H, OCH3), 3.82 (s, 2H, COCH2CO), 7.93 (d, 1H, 
3J = 
8.9 Hz, Ar-H4), 8.30 (dd, 1H, 3J = 8.9 Hz, 4J = 2.4 Hz,  Ar-H5), 9.09 (d, 1H, 4J = 2.4 Hz, Ar-
H7), 13.19 (s br, 1H, CONH) ppm; 13C NMR (100 MHz, DMSO-d6) δ 42.21, 52.27, 119.11, 
120.75, 121.77, 132.13, 143.06, 153.27, 163.04, 165.95, 167.16 ppm; HRMS (ESI+) m/z for 
C11H10N3O5S ([M+H]
+): calcd. 296.0341, found 296.0343.  
Methyl 4-((6-nitrobenzo[d]thiazol-2-yl)amino)-4-oxobutanoate (4). Prepared according to 
general procedure A from compound 1 (2.00 g, 10.2 mmol); yellow crystals, yield 2.00 g (63 %); 
 
 
 
 
 
mp 231-234 °C; IR (ATR) ν 3259. 3107, 2967, 2923, 2362, 1719, 1667, 1576, 1538, 1508, 1440, 
1430, 1336, 1272, 1212, 1154, 1132, 1071, 1044, 1016, 997, 954, 908, 829 cm-1; 1H NMR (400 
MHz, DMSO-d6) δ  2.70 (m, 2H, COCH2), 2.83 (m, 2H, COCH2), 3.62 (s, 3H, OCH3), 7.88 (d, 
1H, 3J = 8.9 Hz, Ar-H4), 8.27 (dd, 1H, 3J = 8.9 Hz, 
4J = 2.4 Hz,  Ar-H5), 9.03 (d, 1H, 4J = 2.4 
Hz, Ar-H7), 12.86 (s br, 1H, CONH) ppm; 13C NMR (100 MHz, DMSO-d6) δ 27.83, 30.08, 
51.52, 119.00, 120.51, 121.72, 132.11, 142.89, 153.45, 163.30, 171.84, 172.50 ppm; HRMS 
(ESI+) m/z for C12H12N3O5S ([M+H]
+): calcd. 310.0498, found 310.0495.           
General procedure B. Synthesis of compounds 5, 6 and 7. Catalytic hydrogenation of 
compound 2 (1.00 mmol in 10 mL methanol) and compounds 3 and 4 (1.00 mmol in 10 mL 
ethanol) were performed in the presence of 10% Pd/C (0.030 g) as a catalyst at room temperature 
and atmospheric pressure for 24 h. At the end of the reaction, the reaction mixture was filtered 
and the filtrate was concentrated to give the crude products which were recrystallized from 
methanol (compound 5) or ethanol (compounds 6, 7).   
Ethyl 2-((6-aminobenzo[d]thiazol-2-yl)amino)-2-oxoacetate (5). Prepared according to general 
procedure B from compound 2 (0.850 g, 2.88 mmol); greenish crystals, yield 0.698 g (91 %); mp 
147-150 °C; IR (ATR) ν 3268, 2988, 2362, 1733, 1688, 1604, 1549, 1464, 1393, 1367, 1296, 
1258, 1160, 1112, 1058, 1011, 964, 907, 865, 812, 802 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
1.31 (t, 3H, J = 7.1 Hz, CH2CH3), 4.31 (q, 2H, J = 7.1 Hz, CH2CH3), 5.34 (s br, 2H, NH2), 6.76 
(dd, 1H, 3J = 8.6 Hz, 
4J = 2.1 Hz,  Ar-H5), 7.05 (d, 1H, 4J = 2.1 Hz, Ar-H7), 7.47 (d, 1H, J = 8.6 
Hz, Ar-H4), 12.82 (s br, 1H, CONH); 13C NMR (100 MHz, DMSO-d6): δ 13.74, 62.51, 103.94, 
114.88, 120.88, 132.99, 138.48, 146.31, 152.84, 156.77, 159.41 ppm; HRMS (ESI+) m/z for 
C11H12N3O3S ([M+H]
+): calcd. 266.0599, found 266.0602.    
 
 
 
 
 
Methyl 3-((6-aminobenzo[d]thiazol-2-yl)amino)-3-oxopropanoate (6). Prepared according to 
general procedure B from compound 3 (1.50 g, 5.08 mmol); brownish crystals, yield 0.825 g (61 
%); mp 162-165 °C; IR (ATR) ν 3381, 2958, 2361, 2342, 1726, 1683, 1608, 1555, 1464, 1433, 
1408, 1331, 1310, 1285, 1252, 1233, 1212, 1175, 1141, 1057, 1015, 978, 909, 866, 780 cm-1; 1H 
NMR (400 MHz, DMSO-d6) δ 3.62 (s, 2H, COCH2CO), 3.67 (s, 3H, OCH3), 5.24 (s br, 2H, 
NH2), 6.72 (dd, 1H, 
3J = 8.6 Hz,  
4J = 2.1 Hz, Ar-H5), 7.01 (d, 1H, 
4J = 2.1 Hz, Ar-H7), 7.42 (d, 
1H, 3J = 8.6 Hz, Ar-H4), 12.23 (s br, 1H, CONH) ppm; 13C NMR (100 MHz, DMSO-d6) δ 
42.10, 52.14, 103.97, 114.49, 120.99, 132.92, 139.43, 145.91, 152.51, 164.41, 167.51 ppm; 
HRMS (ESI+) m/z for C11H12N3O3S ([M+H]
+): calcd. 266.0599, found 266.0606.     
Methyl 4-((6-aminobenzo[d]thiazol-2-yl)amino)-4-oxobutanoate (7). Prepared according to 
general procedure B from compound 4 (0.700 g, 2.26 mmol); brownish crystals, yield 0.440 g 
(70 %); mp 208-211 °C; IR (ATR) ν 3201, 2988, 2947, 2362, 1727, 1687, 1607, 1575, 1556, 
1472, 14737, 1422, 1387, 1311, 1271, 1232, 1151, 1081, 1060, 999, 983, 915, 898 cm-1; 1H 
NMR (400 MHz, DMSO-d6) δ 2.64 (m, 2H, COCH2), 2.72 (m, 2H, COCH2), 3.61 (s, 3H, 
OCH3), 5.16 (s br, 2H, NH2), 6.70 (dd, 1H, 
3J = 8.6 Hz, 4J = 2.3 Hz, Ar-H5), 6.99 (d, 1H, 4J = 
2.3 Hz, Ar-H7), 7.40 (d, 1H, 3J = 8.6 Hz, Ar-H4), 12.07 (s, 1H, CONH) ppm; 
13C NMR (100 
MHz, DMSO-d6) δ 28.00, 29.81, 51.43, 104.03, 114.34, 120.78, 132.85, 139.56, 145.68. 152.87, 
170.26, 172.59 ppm; HRMS (ESI+) m/z for C12H14N3O3S ([M+H]
+): calcd. 280.0756, found 
280.0758.    
 General procedure C. Synthesis of compounds 8-12. To a solution of 4,5-dibromo-1H-
pyrrole-2-carboxylic acid (for 8, 9 and 10) (0.250 g, 0.930 mmol)  or 4,5-dichloro-1H-pyrrole-2-
carboxylic acid (for 11 and 12) (0.167 g, 0.930 mmol)  in anhydrous dichloromethane (20 mL), 
oxalyl chloride (0.46 mL of 2M solution in methylene chloride, 0.93 mmol) was added and the 
 
 
 
 
 
reaction mixture was stirred for 15 h. The solvent was removed under reduced pressure 
whereupon dichloromethane (15 mL), pyridine (5 mL) appropriate amine (1.00 mmol) were 
added to the residue and stirred for 2 h at room temperature The reaction mixture was 
concentrated and dissolved in ethyl acetate (50 mL) and the solution washed successively with 
1M HCl (10 mL), NaHCO3 (10 mL), water (10 mL) and brine (10 mL). The ethyl acetate phase 
was dried over sodium sulfate and concentrated. The crude products were recrystallized from 
methanol.         
Ethyl 2-((6-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzo[d]thiazol-2-yl)amino)-2-
oxoacetate (8). Prepared according to general procedure C from amine 5 (0.220 g, 0.829 mmol) 
and 4,5-dibromo-1H-pyrrole-2-carbonyl chloride (0.357 g. 1.24 mmol); yellow crystals, yield 
0.220 g (51 %); mp 252-255 °C; IR (ATR) ν 3122, 2971, 2362, 1745, 1703, 1640, 1609, 1574, 
1546, 1521, 1460, 1434, 1410, 1332, 1312, 1251, 1232, 1187, 1163, 1107, 1042, 1014, 984, 974, 
961, 869, 824, 810 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 1.33 (t, 3H, J = 7.1 Hz, CH2CH3), 
4.33 (q, 2H, J = 7.1 Hz, CH2CH3), 7.26 (d, 1H, 
4J = 2.7 Hz, pyrrole-H3), 7.72 (dd, 1H, 3J = 8.8 
Hz, 4J = 2.0 Hz, Ar-H5), 7.79 (d, 1H, 3J = 8.8 Hz, Ar-H4), 8.44 (d, 1H, 4J = 2.0 Hz, Ar-H7), 
10.07 (s, 1H, NHCO), 12.96 (s br, 1H, NHCOCO), 13.17 (s br, 1H, pyrrole-NH) ppm; 13C NMR 
(100 MHz, DMSO-d6) δ 13.75, 62.68, 98.17, 106.02, 112.49, 113.86, 119.78, 120.69, 127.79, 
131.98, 135.35, 144.25, 157.29, 159.03 ppm (2 carbonyl signals not seen due to broadening); 
HRMS (ESI-) m/z for C16H11Br2N4O4S ([M-H]
-): calcd. 512.8868, found 512.8882; HPLC: tr = 
20.94 min (96.3 % at 220 nm).    
Methyl 3-((6-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzo[d]thiazol-2-yl)amino)-3-
oxopropanoate (9). Prepared according to general procedure C from compound 6 (0.200 g, 0.754 
mmol) and 4,5-dibromo-1H-pyrrole-2-carbonyl chloride (0.325 g, 1.13 mmol); yellow crystals, 
 
 
 
 
 
yield 0.225 g (58 %); mp > 340 °C; IR (ATR) ν 3199, 2988, 2361, 1722, 1691, 1643, 1611, 
1575, 1549, 1523, 1468, 1436, 1410, 1370, 1329, 1370, 1254, 1225, 1180, 1148, 1067, 1016, 
973, 869, 815 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 3.68 (s, 5H, OCH3, COCH2CO), 7.26 (d, 
1H, 4J = 2.7 Hz, pyrrole-H3), 7.68 (dd, 1H, 3J = 8.8 Hz, 
4J = 2.0 Hz, Ar-H5), 7.74 (d, 1H, 3J = 
8.8 Hz, Ar-H4), 8.39 (d, 1H, 4J = 2.0 Hz, Ar-H7), 10.02 (s, 1H, NHCO), 12.54 (s, 1H, 
NHCOCH2), 12.94 (d, 1H, 
4J = 2.7 Hz, pyrrole-NH) ppm; 13C NMR (100 MHz, DMSO-d6): δ 
42.16, 52.21, 98.15, 105.93, 112.4, 113.78, 119.51, 120.63, 127.84, 131.85, 134.89, 144.61, 
156.61, 157.24, 165.05, 167.38 ppm; HRMS (ESI-) m/z for C16H11Br2N4O4S ([M-H]
-): calcd. 
512.8868, found 512.8879; HPLC: tr  = 19.07 min (97.1 % at 220 nm).       
Methyl 4-((6-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzo[d]thiazol-2-yl)amino)-4-
oxobutanoate (10). Prepared according to general procedure C from compound 7 (0.318 g, 1.14 
mmol) and 4,5-dibromo-1H-pyrrole-2-carbonyl chloride (0.491 g, 1.71 mmol); yellow crystals, 
yield 0.260 g (43 %); mp. 254-257 °C; IR (ATR) ν 3198, 2988, 2361, 1701, 1647, 1616, 1578, 
1547, 1521, 1473, 1443, 1408, 1357, 1332, 1279, 1259, 1223, 1181, 1154, 1066, 983, 970, 954, 
920, 867 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 2.67 (m, 2H, CH2CO), 2.78 (m, 2H, CH2CO), 
3.62 (s, 3H, OCH3), 7.25 (d, 1H, 
4J = 2.7 Hz, pyrrole-H3), 7.66 (dd, 1H, 3J = 8.8 Hz, 4J = 2.0 Hz,  
Ar-H5), 7.72 (d, 1H, 3J = 8.8 Hz, Ar-H4), 8.36 (d, 1H, 
4J = 2.0 Hz, Ar-H7), 10.00 (s, 1H, 
NHCO), 12.38 (s, 1H, NHCOCH2), 12.93 (d, 1H, 
4J = 2.7 Hz, pyrrole-NH) ppm; 13C NMR (100 
MHz, DMSO-d6) δ 27.94, 29.92, 51.47, 98.14, 105.88, 112.40, 113.75, 119.38, 120.41, 127.87, 
131.81, 134.66, 144.72, 156.92, 157.23, 170.92, 172.56 ppm; HRMS (ESI-) m/z for 
C17H13Br2N4O4S ([M-H]
-): calcd. 526.9024, found 526.9035; HPLC: tr = 20.39 min (97.1 % at 
220 nm).  
 
 
 
 
 
Ethyl 2-((6-(4,5-dichloro-1H-pyrrole-2-carboxamido)benzo[d]thiazol-2-yl)amino)-2-
oxoacetate (11). Prepared according to general procedure C from compound 5 (0.250 g, 0.942 
mmol); yellow crystals, yield 0.230 g (57 %); mp 272-275 °C; IR (ATR) ν 3410, 3173, 2986, 
1752, 1705, 1654, 1608, 1579, 1545, 1521, 1465, 1412, 1339, 1285, 1231, 1188, 1146, 1015, 
961, 868, 812, 747 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 1.33 (t, 3H, J = 7.1 Hz, CH2CH3), 
4.33 (q, 2H, J = 7.1 Hz, CH2CH3), 7.23 (s, 1H, pyrrole-H3), 7.72 (dd, 1H, 
3J = 8.87 Hz, 4J = 2.0 
Hz, Ar-H5), 7.79 (d, 1H, J = 8.8 Hz, Ar-H4), 8.44 (d, 1H, J = 2.0 Hz, Ar-H7), 10.08 (s, 1H, 
NHCO), 13.01 (s br, 1H, NHCOCH2), 13.18 (s br, 1H, pyrrole-NH) ppm; 
13C NMR (100 MHz, 
DMSO-d6) δ 13.75, 62.68, 108.28, 110.93, 112.58, 116.11, 119.83, 120.72, 124.52, 131.96, 
135.28, 143.59, 157.42, 159.05 ppm (2 carbonyl signals not seen due to broadening). HRMS 
(ESI-) m/z for C16H11Cl2N4O4S ([M-H]
-): calcd 424.9878, found 424.9872; HPLC: tr = 20.73 min 
(96.2 % at 220 nm).   
Methyl 3-((6-(4,5-dichloro-1H-pyrrole-2-carboxamido)benzo[d]thiazol-2-yl)amino)-3-
oxopropanoate (12). Prepared according to general procedure C from compound 6 (0.220 g, 
0.829 mmol); yellow crystals, yield 0.195 g (55 %); mp. 332-335 °C; IR (ATR) ν 3285, 3184, 
3041, 2988, 1725, 1691, 1637, 1614, 1575, 1548, 1526, 1461, 1413, 1381, 1254, 1234, 1210, 
1177, 1149, 1082, 1019, 978, 869, 817, 761, 724, 674 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 
3.68 (s, 5H, CH2, OCH3), 7.22 (d, 1H, 
3J = 2.8 Hz, pyrrole-H3), 7.68 (dd, 1H, 3J = 8.8 Hz, 4J = 
2.0 Hz, Ar-H5), 7.74 (d, 1H, 3J = 8.8 Hz, Ar-H4), 8.38 (d, 1H, J = 2.0 Hz, Ar-H7), 10.04 (s, 1H, 
NHCO), 12.54 (s br, 1H, NHCOCH2), 12.98 (d, 1H, 
4J = 2.8 Hz, pyrrole-NH) ppm; 13C NMR 
(100 MHz, DMSO-d6) δ 42.17, 52.20, 108.25, 110.86, 112.53, 116.03, 119.56, 120.62, 124.55, 
131.81, 134.83, 144.64, 156.66, 157.37, 165.07, 167.38 ppm. HRMS (ESI-) m/z for 
 
 
 
 
 
C16H11Cl2N4O4S ([M-H]
-): calcd. 424.9878, found 424.9880; HPLC: tr = 19.58 min (96.4 % at 
220 nm).       
 General procedure D. Synthesis of compounds 13, 14 and 24-29.  Hydrolysis of esters 8, 
10 and 18-23 (1.00 mmol) was performed with 1M NaOH (2.00 mL, 2.00 mmol) in methanol (10 
mL) at room temperature overnight. After evaporation of the methanol, the reaction mixture was 
acidified with 1M HCl to pH 3 and the precipitated carboxylic acids were collected by filtration.                   
2-((6-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzo[d]thiazol-2-yl)amino)-2-oxoacetic acid 
(13). Prepared according to general procedure D from compound 8 (0.105 g, 0.203 mmol); 
brownish crystals, yield 0.051 g (51 %); mp 238-241 °C; IR (ATR) ν 3117, 1703, 1656, 1613, 
1547, 1518, 1478, 1411, 1388, 1293, 1225, 1161, 927, 907, 864, 813, 739, 689 cm-1; 1H NMR 
(400 MHz, DMSO-d6): δ 7.27 (d, 1H, J = 2.8 Hz, pyrrole-H3), 7.71 (dd, 1H,  
3J = 8.7 Hz, 4J = 
2.0 Hz, Ar-H5), 7.78 (d, 1H, 3J = 8.7 Hz, Ar-H4), 8.44 (d, 1H, 4J = 2.0 Hz, Ar-H7), 10.06 (s, 1H, 
NHCO), 12.94 (s br, 1H, NHCOCO), 12.95 (d, 1H, 4J = 2.8 Hz, pyrrole-NH) ppm, signal for 
COOH not observed; 13C NMR (100 MHz, DMSO-d6) δ 98.17, 105.97, 112.40, 113.89, 119.68, 
120.85, 127.81, 132.09, 135.27, 144.41, 156.28, 157.27, 158.40, 160.69 ppm; HRMS (ESI-) m/z 
for C14H7Br2N4O4S ([M-H]
-): calcd 484.8555, found 484.8550; HPLC: tr = 17.02 min (97.4 % at 
220 nm).   
4-((6-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzo[d]thiazol-2-yl)amino)-4-oxobutanoic 
acid (14). Prepared according to general procedure D from compound 10 (0.110 g, 0.207 mmol); 
brownish crystals, yield 0.039 g (36 %); mp. 285-288 °C; IR (ATR) ν 3203, 2971, 1660, 1615, 
1574, 1547, 1515, 1472, 1405, 1367, 1333, 1311, 1284, 1254, 1215, 1159, 1066, 1010, 973, 917, 
867, 844, 805, 743, 715 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 2.59 (m, 2H, CH2CO), 2.73 (m, 
 
 
 
 
 
2H, CH2CO), 7.25 (d, 1H, J = 2.7 Hz, pyrrole-H3), 7.66 (dd, 1H, 
3J = 8.8 Hz, 
4J= 2.0 Hz, Ar-
H5), 7.71 (d, 1H, 3J = 8.8 Hz, Ar-H4), 8.36 (d, 1H, 4J = 2.0 Hz, Ar-H7), 10.00 (s, 1H, NHCO), 
12.35 (s br, 2H, NHCOCH2. COOH), 12.93 (d, 1H, 
4J = 2.8 Hz, pyrrole-NH) ppm; 13C NMR 
(100 MHz, DMSO-d6) δ 28.25, 30.06, 98.14, 105.87, 112.40, 113.75, 119.38, 120.38, 127.87, 
131.79, 134.63, 144.73, 156.97, 157.22, 171.18, 173.53 ppm; HRMS (ESI-) m/z for 
C16H11Br2N4O4S ([M-H]
-): calcd. 512.8868, found 512.8881; HPLC: tr = 17.00 min (95.2 % at 
220 nm).          
Benzo[d]thiazole-2,6-diamine (15). 10% Pd/C (0.195 g) was added to a solution of 6-
nitrobenzo[d]thiazol-2-amine (1) (1.95 g, 10.0 mmol) in ethanol (100 mL) and hydrogenated in 
Parr hydrogenator at 2.1 bar pressure at room temperature for 6 h. The reaction mixture was 
filtered through celite and cotton and the filtrate was evaporated under reduced pressure to give 
benzo[d]thiazole-2,6-diamine (15) (1.59 g, 96 % yield). 1H NMR (400 MHz, DMSO-d6) δ 4.79 
(s br, 2H, 6-NH2, 6.45 (dd, 1H, 
3J = 8.4 Hz, 
4J = 2.2 Hz, Ar-H5), 6.81 (d, 1H, 4J = 2.2 Hz, Ar-
H7), 6.93 (s br, 2H, 2-NH2), 7.03 (d, 1H, J = 8.4 Hz, Ar-H4) ppm. 
General procedure E. Synthesis of compounds 16 and 17. Benzo[d]thiazole-2,6-diamine (15) 
(0.714 g, 4.32 mmol) and Na2CO3 (0.458 g, 4.32 mmol) were dissolved in N,N-
dimethylformamide (30 mL) and the mixture was heated to 80 °C. 2,2,2-Trichloro-1-(4,5-
dibromo-1H-pyrrol-2-yl)ethan-1-one (1.60 g, 4.32 mmol) or 2,2,2-trichloro-1-(4,5-dichloro-1H-
pyrrol-2-yl)ethan-1-one (1.22 g, 4.32 mmol) was added and the mixture stirred for 5 h at 80 °C.  
Solvent was removed under reduced pressure and the residue was recrystallized from EtOAc to 
obtain compound 16 or 17.  
 
 
 
 
 
N-(6-Aminobenzo[d]thiazol-2-yl)-4,5-dibromo-1H-pyrrole-2-carboxamide (16). Prepared 
according to general procedure E from 15 and 2,2,2-trichloro-1-(4,5-dibromo-1H-pyrrol-2-
yl)ethan-1-one; yellow crystals, yield 1.35 g (75 %); mp 269-271 °C; IR (ATR) ν 2971, 2362, 
1687, 1649, 1611, 1556, 1470, 1405, 1381, 1318, 1298, 1276, 1244, 1174, 1137, 1057, 991, 974, 
938, 914, 865, 823 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 5.23 (s, 2H, 6-NH2), 6.73 (dd, 1H, 
3J 
= 8.6, 4J = 2.0 Hz, Ar-H5), 7.03 (d, 1H, 4J = 2.0 Hz, Ar-H7), 7.43 (d, 1H, 3J = 8.6 Hz, Ar-H4), 
7.45 (s, 1H, pyrrole-H3), 12.18 (s br, 1H, NH), 13.12 (s br, 1H, NH) ppm; 13C NMR (100 MHz, 
DMSO-d6): δ 98.83, 103.98, 107.94, 114.44, 115.49, 120.59, 126.03, 133.01, 139.44, 145.82, 
153.35, 156.82  ppm, HRMS (ESI-) m/z for C12H7Br2N4OS ([M-H]
-): calcd 412.8707, found 
412.8708; HPLC: tr = 17.34 min (100 % at 254 nm).  
N-(6-Aminobenzo[d]thiazol-2-yl)-4,5-dichloro-1H-pyrrole-2-carboxamide (17). Prepared 
according to general procedure E from 15 and 2,2,2-trichloro-1-(4,5-dichloro-1H-pyrrol-2-
yl)ethan-1-one; yellow crystals, yield 1.10 g (78 %); mp 275-278 °C; IR (ATR) ν 3126, 2988, 
2362, 1659, 1614, 1553, 1473, 1419, 1392, 1327, 1295, 1278, 1182, 1132, 1057, 1020, 992, 937, 
862, 824, 724 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 5.22 (s, 2H, 6-NH2), 6.73 (dd, 1H, 
3J = 
8.6, 4J = 2.0 Hz, Ar-H5), 7.03 (d, 1H, 4J = 2.0 Hz, Ar-H7), 7.42 (s, 1H, pyrrole-H3), 7.43 (d, 1H, 
3J = 8.6 Hz, Ar-H4), 12.19 (s br, 1H, NH), 13.22 (s br, 1H, NH) ppm; 13C NMR (100 MHz, 
DMSO-d6) δ 104.00, 108.90, 112.58, 114.46, 117.76, 120.58, 122.72 132.99, 139.41, 145.80, 
153.37, 156.99 ppm; HRMS (ESI-) m/z for C12H7Cl2N4OS ([M-H]
-): calcd 324.9718, found 
324.9709; HPLC: tr = 17.09 min (97.3 % at 254 nm).      
General procedure F. Synthesis of compounds 18-23. To a solution of compound 16 (0.220 g, 
0.529 mmol) (for 18, 19, 20) or compound 17 (0.173 g, 0.529 mmol) (for 21, 22, 23) and 
triethylamine (0.10 mL, 0.79 mmol) in 1,4-dioxane (20 mL) cooled to 0 °C, ethyl oxalyl chloride 
 
 
 
 
 
(0.089 mL, 0.79 mmol), methyl malonyl chloride (0.084 mL, 0.79 mmol) or methyl succinyl 
chloride (0.097 mL, 0.79 mmol) were added dropwise and the reaction mixture was stirred for 
additional 3 h at room temperature. Saturated NaHCO3 solution was added to quench the 
reaction. The mixture was concentrated, dissolved in ethyl acetate (25 mL) and the solution was 
washed with saturated NaHCO3 solution (3 × 10 mL), 10% citric acid (3 × 10 mL), water (3 × 10 
mL) and brine (3 × 10 mL). If the product precipitated between the ethyl acetate and water phase 
it was collected by filtration. The ethyl acetate phase was dried over sodium sulfate and 
concentrated in vacuo. The crude products were recrystallized from ethyl acetate.  
Ethyl 2-((2-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-2-
oxoacetate (18). Prepared according to general procedure F from compound 16 (0.220 g, 0.529 
mmol) and ethyl oxalyl chloride (0.089 mL, 0.79 mmol); yellow crystals, yield 0.230 g (84 %); 
mp 273-276 °C; IR (ATR) ν 3333, 3297, 3125, 2362, 1711. 1655, 1610, 1560, 1520, 1470, 1437, 
1409, 1382, 1324, 1303, 1277, 1228, 1179, 1112, 1059, 1014, 998, 979, 880, 861, 836, 815, 805 
cm -1;  1H NMR (400 MHz, DMSO-d6 + TFA) δ 1.33 (t, 3H, J = 7.1 Hz, CH2CH3), 4.32 (q, 2H, J 
= 7.1 Hz, CH2CH3), 7.51 (s, 1H, pyrrole-H3) 7.72 (d, 1H, 
3J = 8.8 Hz, Ar-H4), 7.77 (dd, 1H, 3J = 
8.8 Hz, 4J = 2.0 Hz, Ar-H5), 8.41 (d, 1H, 4J = 2.0 Hz, Ar-H7), 10.97 (s, 1H, NHCOCO), 12.62 (s 
br, 1H, NH), 13.27 (s br, 1H, J = Hz, NH) ppm; 13C NMR (100 MHz, DMSO-d6): δ 13.83, 
62.42, 99.04, 108.55, 113.09, 116.10, 119.83, 120.33, 125.61, 131.90, 133.35., 145.64, 155.46, 
157.03, 157.95, 160.66 ppm; HRMS (ESI-) m/z for C16H11Br2N4O4S ([M-H]
-): calcd 512.8868, 
found 512.8864; HPLC: tr = 21.97 min (98.7 % at 254 nm). 
Methyl 3-((2-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-3-
oxopropanoate (19). Prepared according to general procedure F from compound 16 (0.434 g, 
1.04 mmol) and methyl malonyl chloride (0.18 mL, 1.6 mmoL); yellow crystals, yield 0.330 g 
 
 
 
 
 
(61 %); mp. 261-263 °C; IR (ATR) ν 3309, 2988, 2362, 1708, 1657, 1614, 1579, 1538, 1472, 
1440, 1384, 1359, 1318, 1297, 1278, 1262, 1214, 1172, 1103, 1057, 996, 977, 940, 906, cm -1; 
1H NMR (400 MHz, DMSO-d6) δ 3.52 (s, 2H, COCH2CO), 3.67 (s, 3H, OCH3), 7.50 (s br, 1H, 
pyrrole-H3), 7.53 (dd, 1H, 3J = 8.7 Hz, 4J = 1.8 Hz, Ar-H5), 7.70 (d, 1H, 3J = 8.7 Hz, Ar-H4), 
8.31 (d, 1H, 4J = 1.8 Hz, Ar-H7),  10.43 (s, 1H, NHCOCH2), 12.57 (s br, 1H, NH), 13.24 (s br, 
1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6): δ 43.42. 51.97, 99.00, 108.50, 111.48, 115.97, 
118.51, 120.38, 125.67, 132.11, 134.81, 144.81, 157.01, 157.44, 163.91, 168.13 ppm; HRMS 
(ESI-) m/z for C16H11Br2N4O4S ([M-H]
-): calcd 512.8868, found 512.8854; HPLC: tr = 20.59 min 
(99.4 % at 254 nm).  
Methyl 4-((2-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-4-
oxobutanoate (20). Prepared according to general procedure F from compound 16 (0.125 g, 
0.300 mmol) and succinyl chloride (0.050 mL, 0.45 mmol). Yellow crystals, yield: 0.055 g (34 
%); mp 139-141 °C; IR (ATR)  ν 3364, 1718, 1660, 1612, 1578, 1533, 1470, 1436, 1408, 1382, 
1316, 1276, 1205, 1170 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 28.46, 30.79, 51.36, 99.00, 
108.46, 111.14, 115.93, 118.39, 120.36, 125.69, 132.04, 135.32, 144.43, 157.09, 157.44, 169.74, 
172.86 ppm 2.59-2.68 (m, 4H, COCH2CH2CO), 3.61 (s, 3H, OCH3), 7.51-7.54 (m, 2H, pyrrole-
H3, Ar-H5), 7.69 (d, 1H, 3J = 8.1 Hz, Ar-H4), 8.32 (d, 1H, 4J = 1.8 Hz, Ar-H7),  10.19 (s, 1H, 
NHCOCH2), 12.56 (s, 1H, NH), 13.23 (s, 1H, NH)  ppm; 
13C NMR NMR (100 MHz, DMSO-d6) 
δ HRMS (ESI+) m/z for C17H15Br2N4O4S ([M+H]
+): calcd 528.9181, found 528.9190; HPLC: tr 
= 20.70 min (100% at 254 nm).  
Ethyl 2-((2-(4,5-dichloro-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-2-
oxoacetate (21). Prepared according to general procedure F from compound 17 (0.150 g, 0.458 
mmol) and ethyl oxalyl chloride (0.077 mL, 0.69 mmol); yellow crystals, yield 0.155 g (79 %); 
 
 
 
 
 
mp 274-277 °C; IR (ATR) ν 3313, 2988, 2362, 1724, 1703, 1652, 1609, 1568, 1528, 1478, 1428, 
1399, 1369, 1323, 1306, 1279, 1230, 1191, 1115, 1064, 1016, 956, 882, 852 cm-1; 1H NMR (400 
MHz, DMSO-d6 + TFA) δ  1.33 (t, 3H, J = 7.1 Hz, CH2CH3), 4.32 (q, 2H, J = 7.1 Hz, CH2CH3), 
7.49 (s, 1H, pyrrole-H3) 7.73 (d, 1H, 3J = 8.7 Hz, Ar-H4), 7.78 (dd, 1H, 3J = 8.7 Hz, 4J = 2.0 Hz, 
Ar-H5), 8.41 (d, 1H, 4J = 2.0 Hz, Ar-H7), 10.97 (s, 1H, COCONH), 12.66 (s br, 1H, NH), 13.35 
(s br, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6): δ 13.82, 62.43, 109.10, 113.12, 113.19, 
118.34, 119.85, 120.39, 122.32, 131.91, 133.35, 145.64, 155.48, 157.25, 158.01, 160.64 ppm; 
HRMS (ESI-) m/z for C16H11Cl2N4O4S ([M-H]
-): calcd 424.9878, found 424.9889; HPLC: tr = 
21.59 min (96.3 % at 254 nm).  
Methyl 3-((2-(4,5-dichloro-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-3-
oxopropanoate (22). Prepared according to general procedure F from compound 17 (0.150 g, 
0.458 mmol) and methyl malonyl chloride (0.074 mL, 0.69 mmol); yellow crystals, yield 0.120 g 
(61 %); mp. 281-284 °C; IR (ATR) ν 3343,2988, 2361, 1705, 1662, 1617, 1582, 1565, 1543, 
1474, 1434, 1411, 1393, 1360, 1326, 1281, 1264, 1224, 1179, 1108, 1057, 1021, 1002, 946, 879 
cm-1; 1H NMR (400 MHz, DMSO-d6) δ 3.56 (s, 2H, COCH2CO), 3.66 (s, 3H, OCH3), 7.46 (s br, 
1H, pyrrole-H3), 7.58 (dd, 1H, 3J = 8.7 Hz, 4J = 1.9 Hz, Ar-H5), 7.70 (d, 1H, 3J = 8.7 Hz, Ar-
H4), 8.33 (d, 1H, 4J = 1.9 Hz, Ar-H7),  10.68 (s, 1H, NHCOCH2), 12.64 (s br, 1H, NH), 13.35 (s 
br, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6): δ 43.33, 51.93, 108.99, 111.36, 113.14, 
118.28, 118.49, 120.27, 122.51, 131.99, 134.99, 144.69, 157.31, 157.42, 163.99, 168.21 ppm; 
HRMS (ESI-) m/z for C16H11Cl2N4O4S ([M-H]
-): calcd 424.9878, found 424.9890; HPLC: tr = 
20.40 min (96.1 % at 254 nm).   
Methyl 4-((2-(4,5-dichloro-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-4-
oxobutanoate (23). Prepared according to general procedure F from compound 17 (0.150 g, 
 
 
 
 
 
0.458 mmol) and methyl succinyl chloride (0.084 mL, 0.69 mmol); yellow crystals, yield 0.110 g 
(54 %); mp 293-296 °C; IR (ATR) ν 3363, 3118, 1720, 1655, 1611, 1545, 1472, 1419, 1393, 
1328, 1295, 1277, 1234, 1209, 1186, 1141, 1038, 1019, 990, 873, 848, 816, 796, 741 cm -1; 1H 
NMR (400 MHz, DMSO-d6) δ 2.64 (m, 4H, CH2CH2CO), 3.61 (s, 3H, OCH3), 7.48 (s br, 1H, 
pyrrole-H3), 7.53 (dd, 1H, 3J = 8.8 Hz, 4J = 2.0 Hz, Ar-H5), 7.68 (d, 1H, J = 8.8 Hz, Ar-H4), 
8.32 (d, 1H, 4J = 2.0 Hz, Ar-H7),  10.20 (s, 1H, CONHCH2, 12.57 (s br, 1H, NH), 13.30 (s br, 
1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6): δ 28.46, 30.80, 51.34, 109.01, 111.07, 113.14, 
118.14, 118.39, 120.19, 122.51, 131.92, 135.44, 144.14, 157.11, 157.34, 169.78, 172.85 ppm;   
HRMS (ESI-) m/z for C17H13Cl2N4O4S ([M-H]
-): calcd 439.0035, found 439.0040; HPLC: tr = 
20.85 (97.8 % at 254 nm).     
2-((2-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-2-oxoacetic acid 
(24). Prepared by alkaline hydrolysis of ethyl ester 18 (0.080 g, 0.15 mmol) according to general 
procedure D; yield 0.040 g (53 %); mp 276-279 °C; IR (ATR) ν 3112, 2925, 1653, 1610, 1555, 
1470, 1375, 1320, 1278, 1172, 977, 868, 809, 738, 547 cm -1; 1H NMR (400 MHz, DMSO-d6) δ  
7.51 (s br, 1H, pyrrole-H3), 7.73 (d, 1H, 3J = 8.7 Hz, Ar-H4), 7.79 (dd, 1H, 3J = 8.7 Hz, 4J = 1.6 
Hz, Ar-H5), 8.43 (d, 1H, 4J = 1.6 Hz, Ar-H7), 10.89 (s, 1H, COCONH), 12.62 (s br, 1H, NH), 
13.25 (s br, 1H, NH), 14.15 (s br, 1H, COOH) ppm; 13C NMR (100 MHz, DMSO-d6) δ 99.02, 
108.57, 112.81, 114.96, 119.67, 120.25, 125.69, 131.85, 133.65, 145.38, 156.79, 157.16, 157.95, 
162.13 ppm; HRMS (ESI-) m/z for C14H7Br2N4O4S ([M-H]
-): calcd 484.8555, found 484.8543; 
HPLC: tr = 20.19 min (95.9 % at 254 nm).  
3-((2-(4,5-Dibromo-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-3-oxopropanoic 
acid (25). Prepared by alkaline hydrolysis of methyl ester 19 (0.090 g, 0.17 mmol) according to 
general procedure D; brownish crystals, yield 0.035 g (40 %); mp 252-255 °C; IR (ATR) ν 3106, 
 
 
 
 
 
2958, 2362, 1683, 1615, 1587, 1558, 1470, 1372, 1316, 1241, 1166, 1143, 992, 977, 940, 865, 
806, 702 cm-1; 1H NMR (400 MHz, DMSO-d6) δ  3.42 (s, 2H, COCH2CO), 7.50 (d, 1H, J = 2.3 
Hz, pyrrole-H3), 7.53 (dd, 1H, 3J = 8.7 Hz, 4J = 1.6 Hz, Ar-H5), 7.70 (d, 1H, J = 8.7 Hz, Ar-H4), 
8.32 (d, 1H, 4J = 1.6 Hz, Ar-H7),  10.33 (s, 1H, NHCOCH2), 12.60 (s br, 2H, NH, COOH), 13.23 
(s br, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6): δ 43.92, 99.00, 108.46, 111.38, 115.96, 
118.48, 120.28, 125.73, 132.04, 134.98, 144.54, 157.12, 157.45, 164.49, 169.28 ppm: HRMS 
(ESI-) m/z for C15H9Br2N4O4S ([M-H]
-): calcd 498.8711, found 498.8714; HPLC: tr = 19.74 min 
(95.9 % at 254 nm).       
4-((2-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-4-oxobutanoic 
acid (26). Prepared by alkaline hydrolysis of methyl ester 20 (0.025 g, 0.047 mmol) according to 
general procedure D; whitish crystals, yield 0.019 g (78 %); mp 315 °C (decomposition); IR 
(ATR) ν 3259, 3123, 2994, 2512, 1879, 1651, 1608, 1557, 1528, 1468, 1408, 1388, 1323, 1297, 
1259, 1221, 1178, 1105, 1082 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 2.55-2.60 (m, 4H, 
COCH2CH2CO), 7.50 (s, 1H, pyrrole-H3), 7.53 (dd, 1H, 
3J = 8.7 Hz, 4J = 2.0 Hz, Ar-H5), 7.69 
(d, 1H, J = 8.7 Hz, Ar-H4), 8.32 (d, 1H, 4J = 2.0 Hz, Ar-H7),  10.16 (s, 1H, NHCOCH2), 12.16 (s 
br, 1H, NH/COOH), 12.56 (s br, 1H, NH/COOH), 13.23 (s br, 1H, NH) ppm; 13C NMR (100 
MHz, DMSO-d6) δ 28.78, 30.98, 98.95, 108.49, 111.08, 115.91, 118.36, 120.21, 125.79, 132.00, 
135.40, 144.22, 157.14, 157.16, 170.01, 173.83 ppm; HRMS (ESI-) m/z for C16H11Br2N4O4S 
([M-H]-): calcd 512.8868, found 512.8854;  HPLC: tr = 19.96 min (96.3 % at 254 nm). 
2-((2-(4,5-Dichloro-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-2-oxoacetic acid 
(27). Prepared by alkaline hydrolysis of ethyl ester 21 (0.085 g, 0.20 mmol) according to general 
procedure D; grey crystals, yield 0.045 g (57 %); mp. 320-322 °C; IR (ATR) ν 3369, 2971, 2900, 
2361, 1691, 1609, 1560, 1521, 1458, 1420, 1383, 1334, 1310, 1262, 1184, 1138, 1109, 1056, 
 
 
 
 
 
1026, 987, 869, 810, 728 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 7.48 (s, 1H, pyrrole-H3), 7.73 
(d, 1H, 3J = 8.8 Hz, Ar-H4), 7.79 (dd, 1H, 3J = 8.8 Hz, 4J = 1.8 Hz, Ar-H5), 8.43 (d, 1H, 4J = 1.8 
Hz, Ar-H7), 10.86 (s, 1H, NHCOCO), 12.64 (s br, 1H, NH), 13.32 (s br, 1H, NH) ppm, signal 
for COOH not observed; 13C NMR (100 MHz, DMSO-d6) δ 109.07, 112.74, 113.11, 118.32, 
119.63, 120.20, 122.40, 131.83, 133.73, 145.22, 157.13, 157.35, 157.91, 162,16 ppm; HRMS 
(ESI-) m/z for C14H7Cl2N4O4S ([M-H]
-): calcd 396.9565, found 396.9569; HPLC: tr = 20.05 min 
(96.7 % at 254 nm).     
3-((2-(4,5-Dichloro-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-3-oxopropanoic 
acid (28). Prepared from compound 22 (0.100 g, 0.234 mmol) according to general procedure D; 
brownish crystals, yield 0.045 g (46 %); mp. 240-243 °C. IR (ATR) ν 3110, 1679, 1613, 1545, 
1468, 1417, 1392, 1373, 1322, 1256, 1173, 1143, 1021, 991, 939, 867, 805, 703 cm-1; 1H NMR 
(400 MHz, DMSO-d6) δ  3.40 (s, 2H, COCH2CO), 7.48 (d, 1H, 
4J = 2.3 Hz, pyrrole-H3), 7.54 
(dd, 1H, 3J = 8.7 Hz, 4J = 1.7 Hz, Ar-H5), 7.70 (d, 1H, 3J = 8.7 Hz, Ar-H4), 8.32 (d, 1H, 4J = 1.7 
Hz, Ar-H7),  10.33 (s, 1H, NHCOCH2), 12.60 (s br, 2H, NH, COOH), 13.31 (s br, 1H, NH) ppm; 
13C NMR (100 MHz, DMSO-d6): δ 43.93, 109.05, 111.38, 113.05, 118.24, 118.48, 120.28, 
122.45, 132.03, 135.01, 144.50, 157.33, 157.46, 164.48, 169.28 ppm; HRMS (ESI-) m/z for 
C15H9Cl2N4O4S ([M-H]
-): calcd 410.9722, found 410.9712; HPLC: tr = 19.04 min (97.5 % at 254 
nm).  
4-((2-(4,5-Dichloro-1H-pyrrole-2-carboxamido)benzo[d]thiazol-6-yl)amino)-4-oxobutanoic 
acid (29). Prepared from compound 23 (0.050 g, 0.11 mmol) according to general procedure D; 
grey crystals, yield 0.025 g (52 %); mp 298-301 °C; IR (ATR) ν 3254, 2988, 2362, 1655, 1609, 
1552, 1529, 1469, 1420, 1397, 1331, 1302, 1260, 1231, 1184, 1057, 1023, 981, 872, 841, 820, 
742 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 2.60 (m, 4H, CH2CH2CO), 7.48 (s br, 1H, pyrrole-
 
 
 
 
 
H3), 7.54 (dd, 1H, 3J = 8.7 Hz, 4J = 1.8 Hz, Ar-H5), 7.69 (d, 1H, J = 8.7 Hz, Ar-H4), 8.32 (d, 
1H, 4J = 1.8  Hz, Ar-H7),  10.18 (s, 1H, CONHCH2, 11.80-12.80 (s br, 2H, COOH, NH), 13.30 
(s br, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) δ 28.78, 30.97, 109.04, 111.09, 113.02, 
118.19, 118.38, 120.21, 122.47, 131.97, 135.44, 144.12, 157.13, 157.15, 170.02, 173.82 ppm; 
HRMS (ESI-) m/z for C16H11Cl2N4O4S ([M-H]
-): calcd 424.9878, found 424.9873; HPLC: tr = 
19.32 min (97.5 % at 254 nm).   
Evaluation of inhibitory activities on E. coli and S. aureus DNA gyrase. Commercially 
available assay (Inspiralis) for the determination of IC50 values (Inspiralis) was used on 
streptavidin-coated black 96-well microtiter plates (Thermo Scientific Pierce). Wash buffer [137 
mM NaCl, 20 mM Tris-HCl (pH 7.6), 0.01 % (w/v) BSA, 0.05 % (v/v) Tween 20] was used to 
rehydrate the plates and then biotinylated oligonucleotide was immobilized onto the plates. Wash 
buffer was used to remove the non-bound oligonucleotide. The assay was carried out with the 
final volume of 30 μL in buffer [35 mM Tris-HCl (pH 7.5), 24 mM KCl, 4 mM MgCl2, 2 mM 
DTT, 1.8 mM spermidine, 1mM ATP, 6.5 % (w/v) glycerol, 0.0001 g/mL albumin] containing 
1.5 U of gyrase from E. coli or S. aureus, 0.75 μg of relaxed pNO1 plasmid, and inhibitor (in 
3μL of 10 % DMSO and 0.008 % Tween 20 solution). After  30 min incubation at 37 °C  the 
enzymatic reaction was terminated with the addition of the TF buffer [50 mM NaOAc (pH 5.0), 
50 mM NaCl, and 50 mM MgCl2], and left for another 30 min at room temperature to allow the 
formation of biotin-oligonucleotide-plasmid triplex and then TF buffer was used to wash off the 
unbound plasmid. 200 μL of  SybrGOLD stain (diluted 1000 ×) in T10 buffer [10 mM Tris × 
HCl (pH 8.0) and 1 mM EDTA] was added, mixed and the fluorescence (λex = 485 nm;  λem = 
535 nm) was measured with BioTek’s Synergy H4 microplate reader. Inhibitor concentrations of 
100 and 10 μM were used for initial screening. For selected compounds, IC50 values were 
 
 
 
 
 
determined with seven concentrations of the inhibitors. GraphPad Prism program was used for 
calculating IC50 value which represents the concentration of inhibitor where the activity of the 
enzyme is reduced by 50%. IC50 values were determined in three independent measurements, 
and their average value is given as a result. As a positive control novobiocin (Sigma-Aldrich) 
[IC50 = 0.17 μM (lit. 0.08 μM)
31, 32 for E. coli gyrase and IC50 = 0.041 μM (lit. 0.01 μM)
 31, 32 for 
S. aureus gyrase] was used.     
Evaluation of inhibitory activities on E. coli and S. aureus topoisomerase IV. 
Commercially available assay (Inspiralis) for the determination of IC50 values was used on 
streptavidin-coated black 96-well microtiter plates (Thermo Scientific Pierce). Wash buffer [137 
mM NaCl, 20 mM Tris-HCl (pH 7.6), 0.01 % (w/v) BSA, 0.05 % (v/v) Tween 20] was used to 
rehydrate the plates and then biotinylated oligonucleotide was immobilized on the plates. Wash 
buffer was used to remove the non-bound oligonucleotide. The assay was carried out with the 
final volume of 30 μL, using buffer [40 mM HEPES (pH 7.6), 100 mM potassium glutamate, 10 
mM magnesium acetate, 10 mM DTT, 1mM ATP, 0.00005 g/mL albumin] containing 1.5 U of 
topoisomerase IV from E.coli or S. aureus, 0.75 μg of supercoiled pNO1 plasmid and inhibitor 
(in 3μL of 10 % DMSO and 0.008 % Tween 20 solution). The mixture was incubated for 30 min 
at 37 °C, then the enzymatic reaction was terminated with the addition of the TF buffer [50 mM 
NaCl, 50 mM NaOAc (pH 5.0), and 50 mM MgCl2], and left for another 30 min at room 
temperature to allow the formation of biotin-oligonucleotide-plasmid triplex, whereupon TF 
buffer was used to wash off the unbound plasmid. 200 μL of SybrGOLD stain (diluted 1000 ×) 
in T10 buffer [10 mM Tris × HCl (pH 8.0) and 1 mM EDTA] was added, mixed and the 
fluorescence (λex = 485 nm; λem = 535 nm) was measured with a BioTek’s Synergy H4 
microplate reader. Inhibitor concentrations of 100 and 10 μM were used for initial screenin. For 
 
 
 
 
 
selected  compounds, IC50 values were determined with seven concentrations of the inhibitors.  
GraphPad Prism program was used for calculating IC50 value, which represents the concentration 
of inhibitor where the activity of the enzyme is reduced by 50%. The IC50 values were 
determined in three independent measurements and their average value is given as a result. As a 
positive control novobiocin [IC50 = 11 μM (lit. 10 μM)
31,32 for E. coli topoisomerase IV and IC50 
= 27 μM (lit. 20 μM)31,32 for S. aureus topoisomerse IV] was used.  
Determination of antibacterial activity. Antimicrobal assays were performed by the broth 
microdilution method following the Clinical Laboratory Standards Instititute (CLSI; Methods for 
Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Approved 
Standards-Ninth Edition; M07-A9, Vol. 32, No. 2) guidelines. In the antibacterial assays the 
following CLSI recommended quality control strains for susceptibility testing were used: 
Enterococcus faecalis (Gram positive, ATCC 29212), Staphylococcus aureus (Gram positive, 
ATCC 25923), Escherichia coli (Gram negative, ATCC 25922) and Pseudomonas aeruginosa 
(Gram negative, ATCC 27853). A final compounds’ concentration of 50 μM (n = 3) was used for 
determination of their  antimicrobial activity against the ATCC strains.         
Crystallography. Protein production, crystallization, preparation of the inhibitor-protein 
complexes, data collection and processing, structure modeling and refinement were performed 
by Proteros Biostructures GmbH, Martinsread, Germany. 
Protein production. The expression of GyrB was performed according to previously 
established protocols using a suitable previously established construct that allowed production of 
homogenous protein in preparative amounts. The protein was purified using affinity and gel 
 
 
 
 
 
filtration chromatography steps that yielded homogenous protein with a purity better than 95% as 
judged from Coomassie stained SDS-PAGE. 
Crystallization. The purified protein was used in crystallization trials employing both a 
standard screen (ca. 1200 different conditions) as well as crystallization conditions identified in 
literature. Conditions initially obtained have been optimized using standard strategies, 
systematically varying critical parameters influencing crystallization, such as protein 
concentration, temperature, drop ratio, and others. These conditions were also refined by 
systematical variation of pH and precipitant concentrations. 
Data Collection and Processing. A cryo-protocol was established using PROTEROS Standard 
Protocols. Crystals were flash-frozen and measured at the temperature of 100 K. The X-ray 
diffraction data were collected from crystals of complex of the ligand 24 with GyrB at the Swiss 
Light Source (Villigen, Switzerland) using cryogenic conditions. The crystals belonged to space 
group C2. The programs XDS and XSCALE were used for data processing. Tables 3 and 4 
summarize the data collection and refinement statistics. 
 
Table 3. Data collection and processing statistics for compound 24. 
X-ray source PXI/X06SA (SLSa) 
Wavelength [Å] 1.00000 
Detector PILATUS 6M 
Temperature [K] 100 
Space group C 2 
 
 
 
 
 
Cell: a; b; c; [Å] 116.29; 49.58; 70.21 
α; β; γ; [°] 90.0; 93.5; 90.0 
Resolution [Å] 2.83 (3.08-2.83) 
Unique reflections 9437 (2091) 
Multiplicity 2.5 (2.4) 
Completeness [%] 96.7 (96.5) 
Rsym [%]
 7.6 (44.6) 
Rmeas [%]
 9.5 (56.9) 
Mean(I)/sdb 11.17 (3.14) 
 aSWISS LIGHT SOURCE (SLS, Villingen, Switzerland). bCalculated from independent 
reflections. 
 
Table 4. Refinement statistics for compound 24.a 
Resolution [Å] 70.08-2.83 
Number of reflections (working/test) 8772 / 665 
Rcryst [%] 25.8 
Rfree   [%] 
b 28.9 
Total number of atoms:  
    Protein 2807 
    Water 6 
    Ligand 30 
    Iodide 1 
 
 
 
 
 
Deviation from ideal geometry c  
    Bond lengths [Å] 0.007 
    Bond angles   [°] 1.11 
    Bonded B’s [Å2] d 1.3 
Ramachandran plot e  
   Most favored regions [%] 89.9 
   Additional allowed regions [%] 10.1 
   Generously allowed regions [%] 0.0 
   Disallowed regions [%] 0.0 
aValues were defined in REFMAC5, without sigma cutoff. bTest-set contains 6.8% of 
measured reflections. cRoot mean square deviations from geometric target values. dCalculation 
performed with MOLEMAN. eCalculation done with PROCHECK.. 
 
Molecular modeling. 
Ligand and protein preparation. Three-dimensional models of the final compounds were built 
in ChemBio3D Ultra 13.0.33 Their geometries were optimized using MMFF9434 force field, 
partial atomic charges were added and energy  minimized until the gradient value was below 
0.001 kcal/(mol Å). Further refinement with GAMESS interface in ChemBio3D Ultra 13.0 using 
the semi-empirical PM3 method, QA optimization algorithm and Gasteiger-Hückel charges for 
all atoms for 100 steps was performed.34 Molecular docking of the final molecules was 
performed using FlexX,35, 36  as available in LeadIT,37 running on four octal core AMD Opteron 
CPU processors, 16 GB RAM, two 750 GB hard drives, under 64-bit Scientific Linux 6.0. 
Receptor Wizard in LeadIT was used for protein preparation. The binding site was defined as 
 
 
 
 
 
amino acid residues within a radius of 7 Å around an X-ray crystal structure ligand (PDB entry: 
4DUH).22 Correct tautomers and protonation states were assigned and hydrogen atoms were 
added to the binding site residues using the Receptor Wizard. The ligand and water molecules, 
except HOH614, were deleted from the X-ray structure of the complex.  
Ligand docking. The FlexX  hybrid algorithm (enthalpy and entropy driven ligand binding), as 
available in LeadIT,37 was used to place the ‘base fragment’. The maximum number of solutions 
per iteration and the maximum number of solutions per fragmentation parameter values were 
increased to 1000, while other parameters were set at their default values. Docking binding 
modes of the top five highest scored docking poses per ligand were evaluated and the highest 
ranked binding pose was used for graphical representation in PyMOL.38 
 
Screening against PAINS. To evaluate a library of the synthesized compounds against 
PAINS,40 all tested compounds were screened against the PAINS filter using Python script 
filter_pains.py, downloaded from GitHub (https://github.com/Team-
SKI/snippets/blob/1d1d0424ba15da08cdc7e18c9a27d55b1a6cb797/Python/filter_pains.py). All 
compounds passed the PAINS filter. 
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